Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy-Reference-Cited by-同舟云学术

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy

Published:2005-10-01 Issue:7 Volume:104 Page:1548-1555
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Herrstedt Jørn,Muss Hyman B.,Warr David G.,Hesketh Paul J.,Eisenberg Peter D.,Raftopoulos Harry,Grunberg Steven M.,Gabriel Munir,Rodgers Anthony,Hustad Carolyn M.,Horgan Kevin J.,Skobieranda Franck,

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference19 articles.

1. Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the Perugia Consensus Conference

2. Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines

3. ESMO Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV)

4. The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

5. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dexamethasone-sparing strategies in anthracycline and cyclophosphamide-based chemotherapy with a focus on 5-HT3 receptor antagonists: a network meta-analysis;Frontiers in Oncology;2024-07-26

2. Efficacy and safety of Aprepitant-containing triple therapy for the prevention and treatment of chemotherapy-induced nausea and vomiting: A meta-analysis;Medicine;2023-11-24

3. Netupitant/palonosetron (NEPA; Akynzeo®) combination in prevention of the nausea and vomiting in patients with breast cancer receiving anthracyclinbased chemotherapy;Tumors of female reproductive system;2023-10-27

4. Fosaprepitant Weekly vs Every 3 Weeks for the Prevention of Concurrent Chemoradiotherapy–Induced Nausea and Vomiting;JAMA Network Open;2023-07-27

5. Neurogenic Inflammation: The Participant in Migraine and Recent Advancements in Translational Research;Biomedicines;2021-12-30